The Company leases its office facilities, located in Concord, California and Amersfoort, the Netherlands, and certain equipment and automobiles under non-cancelable operating leases with initial terms in excess of one year that require the Company to pay operating costs, property taxes, insurance and maintenance. The operating leases expire at various dates through 2030, with certain of the leases providing for renewal options, provisions for adjusting future lease payments based on the consumer price index, and the right to terminate the lease early. We do not assume renewals in our determination of the lease term unless the renewals are deemed to be reasonably assured at lease commencement. The Company recorded the lease right-of-use asset and obligation at the present value of lease payments over the lease term. The rates implicit in the Company’s leases are generally not readily determinable. The Company must estimate its incremental borrowing rate to discount the lease payments to present value. Operating lease assets also include lease incentives.

Supplemental cash flow information related to operating leases is as follows (dollars in thousands):

	Six Months Ended
	June 30, 2019
Cash payments for operating leases	$	1,693
Right-of-use assets obtained in exchange for operating lease obligations		12,865

	June 30, 2019
Weighted-average remaining lease term	9.7 years
Weighted-average discount rate		9.0	%

Future minimum non-cancelable payments under operating leases as of June 30, 2019, were as follows (in thousands):

	Operating Leases
Remainder of 2019	$	1,819
2020		3,084
2021		3,113
2022		2,741
2023		2,617
Thereafter		18,690
Total future lease payments	$	32,064
Less imputed interest		11,631
Present value of lease liabilities	$	20,433

During the three months ended June 30, 2019 and 2018, the Company recorded operating lease expenses of $0.9 million and $0.3 million, respectively. During the six months ended June 30, 2019 and 2018, the Company recorded operating lease expenses of $1.5 million and $0.7 million, respectively. As of June 30, 2019, the Company had no leases that have not yet commenced.

The Company is party to agreements with certain providers for certain components of the INTERCEPT Blood System. Certain of these agreements require minimum purchase commitments from the Company.